Food Allergies and Asthma: Why the Combination Is Dangerous — and What to Do About It

How Common Is the Food Allergy-Asthma Overlap?

Food allergy and asthma are both expressions of the same underlying immune dysregulation: overactive type 2 (Th2) inflammation mediated by IgE antibodies, eosinophils, mast cells, and the cytokines IL-4, IL-5, and IL-13. It is therefore not surprising that the two conditions co-occur far more often than chance would predict.

Epidemiological data from large cohort studies in the United States estimate that:

• Approximately 32–38% of food-allergic individuals also have asthma.
• Among children with asthma, food sensitization is present in 25–40%, though confirmed food allergy (clinically reactive sensitization) is somewhat lower.
• Adults with poorly controlled asthma are significantly more likely to have concurrent food allergies than matched controls without asthma.
• Conversely, having a food allergy doubles to triples the risk of developing asthma in childhood, independent of other atopic conditions.

The connection is even more pronounced at the severe end of both spectra. Patients with severe, difficult-to-control asthma have higher rates of food sensitization, and patients with severe food allergies — those who have experienced anaphylaxis — are more likely to have asthma than those with milder food reactions.

The Shared Immune Pathway: Why These Two Conditions Travel Together

Both food allergy and allergic asthma arise from a common defect in the epithelial barrier and an overactive type 2 immune response. Understanding this shared biology explains not only why the conditions co-occur, but also why treatments that target the underlying pathway — particularly monoclonal antibodies — can address both simultaneously.

Step 1: Barrier Failure and Early Sensitization

In genetically predisposed individuals, defects in skin or mucosal barrier proteins — most notably filaggrin — allow food allergens to penetrate tissue without being processed through normal oral tolerance mechanisms. This epicutaneous sensitization (sensitization through the skin rather than the gut) activates the innate immune alarm cytokines TSLP, IL-25, and IL-33, which in turn drive dendritic cells to promote a Th2 immune profile rather than the tolerogenic Treg/Th1 balance seen in non-allergic individuals.

Step 2: IgE Production and Mast Cell Priming

Th2 polarization triggers B cells to produce allergen-specific IgE antibodies. These IgE molecules bind to high-affinity IgE receptors (FcεRI) on mast cells and basophils throughout the body — in skin, gut mucosa, airway tissue, and blood vessels. The person is now sensitized: their immune system is "armed" against the allergen. No symptoms occur at this stage.

Step 3: Allergen Re-Exposure and Mast Cell Degranulation

When the sensitized person ingests the allergen, it binds to and cross-links the surface IgE on mast cells, triggering rapid degranulation: the release of pre-formed mediators (histamine, tryptase, heparin) and newly synthesized mediators (prostaglandin D2, leukotriene C4, leukotriene D4, platelet-activating factor). In airways already primed by atopic inflammation, this cascade produces:

• Bronchoconstriction — smooth muscle contraction causing airway narrowing
• Airway edema — mucosal swelling that further reduces luminal diameter
• Mucus hypersecretion — goblet cell activation producing viscous plugs
• Cough and wheeze — the clinical hallmarks of the asthmatic response

In asthmatic airways, this response is exaggerated compared to non-asthmatic airways because the baseline level of eosinophilic inflammation, airway hyper-responsiveness, and smooth muscle mass is already elevated. The food-triggered reaction does not need to be as intense to produce severe bronchoconstriction in an asthmatic patient.

Which Foods Most Commonly Trigger Asthma?

Any food to which a person is IgE-sensitized can, in principle, trigger respiratory symptoms. In practice, the foods responsible for the vast majority of food-triggered asthma attacks and respiratory anaphylaxis in the United States align closely with the FDA's "Big 9" major food allergens:

A Special Note for South Florida Patients

Broward County's diverse culinary culture — with abundant Caribbean, Latin American, Asian, and coastal seafood cuisine — means that shellfish, peanuts, tree nuts, and sesame appear frequently in local restaurant foods, sometimes without clear labeling. Patients with food allergies and asthma in the Plantation area should be especially vigilant at restaurants specializing in shrimp, crab, and lobster dishes, as cross-contamination is common and aerosolized shellfish proteins during cooking can trigger symptoms before food is even consumed. The high year-round humidity also promotes mold growth that adds to the overall allergic burden, reducing the threshold at which food allergens trigger reactions.

Cofactors That Amplify Food-Triggered Asthma

One of the most clinically important — and underappreciated — aspects of food allergy-related asthma is the role of cofactors. A cofactor is a condition or substance that, when present at the time of food allergen ingestion, substantially lowers the reaction threshold or amplifies reaction severity. The same quantity of a food allergen that causes only mild symptoms alone may produce severe bronchospasm or full anaphylaxis in the presence of a cofactor.

Why Asthma Control Is a Life-or-Death Issue for Food-Allergic Patients

The data on food anaphylaxis fatalities are stark and consistent across decades of research: asthma is present in 75–95% of victims. The landmark studies by Sampson et al. (1992), Bock et al. (2001), and subsequent registry analyses all converge on this finding. More recent data from the UK's Register of Anaphylaxis Deaths and the U.S. National Registry of Fatal Anaphylaxis reinforce it.

The mechanism is straightforward. During anaphylaxis, mast cell mediators cause bronchospasm in all patients. In patients without asthma, the airway smooth muscle is less hyper-responsive, the baseline eosinophil burden is lower, and the bronchospasm resolves faster with epinephrine. In patients with asthma — especially those with suboptimal controller therapy who are already inflamed at baseline — the same mediator release produces far greater luminal narrowing from a narrower starting point. The bronchospasm is more severe, less responsive to epinephrine, and more likely to require mechanical ventilation.

This has a direct practical implication: optimal asthma control is not merely about quality of life for food-allergic patients — it is about survival margin during accidental allergen exposure. A food-allergic patient with an FEV1 of 95% and well-controlled asthma has far more respiratory reserve during an anaphylactic reaction than one with an FEV1 of 60% and chronic under-treatment.

Diagnosing Food Allergy in the Asthmatic Patient

Evaluation involves several complementary tools. No single test alone is sufficient to confirm clinically meaningful food allergy, and the threshold for investigation should be low in any asthmatic patient with unexplained triggers, difficult-to-control disease, or a history of reaction after eating.

Clinical History

The most important diagnostic tool. Key questions: What symptoms occurred? What foods were eaten and in what quantity? How quickly did symptoms start after eating? Were other factors present (exercise, alcohol, NSAIDs)? Has the reaction been reproducible? What happened when the food was previously tolerated or avoided?

Skin Prick Testing (SPT)

A standardized panel of food allergen extracts is applied to the forearm with a lancet. A wheal ≥3 mm above the negative control at 15 minutes indicates sensitization. SPT has high sensitivity (~85–95%) but moderate specificity — a positive test does not confirm clinical reactivity, especially for plant foods where cross-reactive pollen proteins (pollen-food allergy syndrome) can produce false positives without genuine food allergy.

Serum Food-Specific IgE

ImmunoCAP testing measures IgE antibodies to whole food extracts or specific allergen components. Higher levels correlate with greater probability of clinical reactivity, though no absolute threshold reliably distinguishes reactors from non-reactors. Component-resolved diagnostics (CRD) refine this:

• Peanut: Ara h 2 IgE >0.35 kU/L strongly predicts genuine systemic reactivity; sensitization to Ara h 8 (cross-reactive pollen protein) typically produces only mild oral symptoms
• Hazelnut: Cor a 14 predicts genuine allergy; Cor a 1 predicts pollen-food allergy syndrome
• Shrimp/shellfish: Tropomyosin (Pen a 1) testing increases specificity
• Wheat: Omega-5 gliadin (Tri a 19) is the key WDEIA component

Oral Food Challenge (OFC)

The gold standard. The patient consumes gradually increasing doses of the suspect food under medical supervision, with standardized observation for 2–4 hours. In patients with asthma, pre-challenge spirometry is mandatory; an FEV1 below 70% predicted is generally a contraindication to challenge. Challenges are conducted in facilities with full resuscitation capability including IV epinephrine, oxygen, and airway management equipment.

Pulmonary Function Assessment

Spirometry, bronchodilator reversibility testing, and FeNO (fractional exhaled nitric oxide) are performed as part of asthma characterization, not food allergy diagnosis per se, but they establish baseline airway status critical for risk-stratifying the food-allergic asthmatic patient. See our guide on FeNO testing for asthma phenotyping.

Management: Avoidance, Emergency Preparedness, and Controller Therapy

Strict Allergen Avoidance

The foundation of food allergy management remains strict avoidance of the causative food. In patients with asthma who are at elevated risk of severe reactions, this includes:

• Reading all food labels (including "may contain" advisory warnings for high-risk allergens)
• Communicating allergen needs clearly when dining out; asking about cooking oil, shared fryers, and cross-contact risk
• Avoiding high-risk cuisines and cooking environments (e.g., commercial kitchens cooking shellfish where aerosolized allergens may be present)
• Wearing medical alert identification indicating both food allergy and asthma
• Informing schools, employers, and caregivers of both conditions

Epinephrine Auto-Injectors

Every food-allergic patient with asthma should carry two epinephrine auto-injectors at all times. Prescribing two is standard of care because biphasic reactions can occur hours after the initial reaction, a second dose may be needed before emergency services arrive, and device malfunction — while rare — is possible. Devices should be checked for expiration and replaced promptly. Patients should practice with training devices until administration is automatic under stress.

Asthma Controller Optimization

For food-allergic patients, asthma controller therapy should be treated as non-negotiable and optimized aggressively. The goal is an FEV1 as close to normal as possible, minimal eosinophilic airway inflammation, and no reliance on rescue inhalers as primary control. An asthma action plan (see our guide) should specifically address what to do if respiratory symptoms occur after eating.

Asthma Action Plan Modification for Food Allergic Patients

Standard asthma action plans cover inhaled-allergen and infection triggers. For food-allergic asthmatics, the plan should additionally specify:

• That epinephrine, not albuterol, is first-line for any reaction after eating a suspect food
• That albuterol can be used adjunctively after epinephrine for residual bronchospasm
• What constitutes a biphasic reaction and when to seek emergency care
• How to identify and avoid cofactors (no exercise for 4 hours after eating high-risk foods; avoid NSAIDs around mealtimes)

Emerging and Biologic Treatments

Omalizumab (Xolair): FDA-Approved for Food Allergy in 2024

Omalizumab is a monoclonal antibody that binds free IgE in the bloodstream, preventing IgE from attaching to FcεRI receptors on mast cells and basophils. By reducing surface IgE receptor expression by up to 97%, it dramatically blunts the mast cell degranulation response to allergen exposure.

In February 2024, the FDA approved omalizumab for a new indication: reducing the risk of allergic reactions — including anaphylaxis — to one or more foods in patients aged 1 year and older with IgE-mediated food allergy. This approval was based on the landmark OUtMATCH trial (NEJM 2024, Nadeau et al.), in which omalizumab-treated participants were significantly more likely to tolerate challenge doses of peanut (67% vs 7% placebo), milk, egg, and cashew after 16 weeks of therapy.

For patients with both food allergy and allergic asthma, omalizumab offers a particularly compelling benefit profile:

Omalizumab does not cure food allergy. Patients must continue strict avoidance and carry epinephrine at all times. However, for food-allergic asthmatics — particularly those with poorly controlled asthma and multiple food allergies — it may be the single most impactful pharmacological intervention available, addressing both conditions through one mechanism.

Dupilumab (Dupixent): Broad Atopic Disease Coverage

Dupilumab blocks the shared IL-4/IL-13 receptor, targeting the upstream cytokines that drive type 2 inflammation across the entire atopic spectrum. It is FDA-approved for moderate-to-severe asthma (eosinophilic or OCS-dependent phenotypes), atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Phase 3 trials in food allergy (OFC endpoints) are underway. Patients who carry the full atopic march — eczema, food allergy, allergic rhinitis, and asthma — may find that dupilumab improves all components simultaneously.

Oral Immunotherapy (OIT) with Omalizumab Pre-Treatment

Oral immunotherapy involves giving gradually escalating doses of the allergen (e.g., peanut flour) under medical supervision to desensitize the patient. FDA-approved Palforzia (peanut OIT) is available for children aged 4–17. Omalizumab pre-treatment before and during OIT is increasingly used to reduce reaction rates during the build-up phase and may allow faster escalation and greater protection. This is an active area of research at academic medical centers; Dr. Hull can discuss whether you or your child may be a candidate.

When to See a Pulmonologist: Red Flags in Food-Allergic Asthmatics

You should seek specialist evaluation with a pulmonologist experienced in asthma management if you have food allergies and any of the following apply:

• Your asthma requires daily rescue inhaler use (more than twice a week on most weeks)
• You have had a prior severe allergic reaction that included respiratory symptoms (wheezing, shortness of breath, throat tightening)
• Your asthma is difficult to control despite adequate inhaled corticosteroid therapy
• Your FeNO is elevated (≥25 ppb) or your blood eosinophil count is high (≥300 cells/µL), suggesting uncontrolled type 2 inflammation
• You are considering oral immunotherapy for food allergy and need pulmonary clearance
• You want evaluation for omalizumab for combined food allergy and asthma indications
• You are unsure whether a prior reaction was food-triggered or purely asthma-triggered

Dr. Frank Hull has over 20 years of experience in pulmonary medicine and severe asthma management, with particular expertise in biologic therapy and type 2 inflammatory disease. The Advanced Asthma Clinic in Plantation, FL provides comprehensive evaluation including spirometry, FeNO testing, allergy referral coordination, and biologic management for South Florida patients with complex asthma.

Practical Guidance: Living With Food Allergies and Asthma in South Florida

Dining Out Safely

South Florida's restaurant culture presents specific challenges for food-allergic asthmatic patients. Practical steps include calling restaurants ahead during non-peak hours to discuss allergen protocols, choosing restaurants with dedicated allergy-aware staff or allergen menus, and being aware that open-kitchen seafood restaurants may aerosolize shrimp or shellfish proteins that can trigger asthma symptoms before any food is ingested. Always bring two epinephrine auto-injectors; do not leave them in the car (Florida heat degrades epinephrine).

Managing the Summer Allergy Burden

Broward County's year-round warm, humid climate sustains high levels of mold, dust mites, and cockroach allergen — all potent asthma triggers that contribute to the baseline type 2 inflammatory burden. Higher aeroallergen load lowers the threshold at which food allergens trigger reactions. During high-mold periods (rainy season, June–October), food-allergic asthmatics should be especially vigilant and ensure asthma controller therapy is at its most effective. See our guide on allergic asthma and South Florida aeroallergens.

Exercise and Eating: The Cofactor Protocol

For patients with exercise-induced food allergy (WDEIA) or any confirmed exercise cofactor effect, the following protocol is widely recommended by allergists:

• Do not exercise within 4 hours of eating foods you are allergic to (or caution foods)
• Always carry epinephrine on exercise outings
• Exercise with a partner who knows your allergy and anaphylaxis plan
• Avoid NSAIDs within 24 hours before planned exercise involving allergen exposure risk
• If you experience any respiratory symptoms during or after exercise, stop, use epinephrine, and call 911

Related reading: The Atopic March: From Eczema to Asthma • Allergic Asthma and Aeroallergens • Asthma and Allergic Rhinitis • Biologic Therapy for Severe Asthma • FeNO Testing • Asthma Phenotypes and Endotypes